Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. (Q40455545)

20 September 2017

title

Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. (English)

1 reference

20 September 2017

1 reference

John R Wingard

1

1 reference

20 September 2017

Helen L Leather

2

1 reference

20 September 2017

Craig A Wood

3

1 reference

20 September 2017

William C Gerth

4

1 reference

20 September 2017

Robert J Lupinacci

5

1 reference

20 September 2017

Marc L Berger

6

1 reference

20 September 2017

Edward C Mansley

7

1 reference

20 September 2017

publication date

1 March 2007

1 reference

American Journal of Health-System Pharmacy

20 September 2017

published in

1 reference

20 September 2017

volume

64

1 reference

20 September 2017

issue

6

1 reference

20 September 2017

page(s)

637-643

1 reference

Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlle

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

Mortality and costs of acute renal failure associated with amphotericin B therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

The direct cost and incidence of systemic fungal infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

The impact of candidemia on length of hospital stay, outcome, and overall cost of illness.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

Economic aspects of treatment for fungal infections in cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

Burden of aspergillosis-related hospitalizations in the United States.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

Excess mortality, length of stay, and costs associated with serious fungal infections among elderly cancer patients: findings from linked SEER-Medicare data

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

Estimating the true cost of amphotericin B

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

Correlates of acute renal failure in patients receiving parenteral amphotericin B.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

Triad of Acute Infusion‐Related Reactions Associated with Liposomal Amphotericin B: Analysis of Clinical and Epidemiological Characteristics

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP050521

31 March 2020

Identifiers

DOI

10.2146/AJHP050521

1 reference

20 September 2017

1 reference